A series of announcements were made by global companies that took part in the 22nd edition of BioAsia 2025, Asia’s largest life sciences and healthcare conference, themed ‘Catalysts of Change – Expanding Global Healthcare Frontiers, Transforming Healthcare with Innovation, Collaboration and Progress’.
While MSD from US has announced the opening of a global tech centre in Hyderabad; US-based Agilisium, a company revolutionising pharma sector by leveraging data-driven insights, has launched its new office at RMZ Spire, Hyderabad. The company has also established a Life Sciences and Innovation & Talent Development Lab.
On the other hand, ALS, an Australia-based global leader in testing, inspection, certification, and verification solutions, is establishing a state-of-the-art Bio Pharma cGMP testing lab in Genome Valley; and Taiwan-based company Lotus is setting up its 2nd R&D centre in Hyderabad.
For Lotus, the new R&D centre will be located in Genome Valley, covering 20,000 square feet and employing around 100 people. The project will be developed in two phases, with the first phase expected to be operational by Q2 2025 and the second phase completed by Q4 2025. To facilitate this expansion, the company has established a new subsidiary called Meishi Pharma Services Private Ltd with an investment of Rs 36 crore.
